Moreover, the total amount of IFN-γ in the spleens resulted significantly increased in STM-treated tumor-bearing mice at 30 days PTI (P < 0.01, Figure 7C) compared to the untreated tumor-bearing mice. This evidence concerns the gene IFNG and neoplasm.